METABOLIC ACTIVATION OF FLUOROPYRROLIDINE DIPEPTIDYL PEPTIDASE-IV INHIBITORS BY RAT LIVER MICROSOMES
Open Access
- 1 January 2005
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (1) , 121-130
- https://doi.org/10.1124/dmd.104.001842
Abstract
The current study evaluated the potential for two dipeptidyl peptidase-IV (DPP-IV) inhibitor analogs (1S)-1-(trans-4-{[(4-trifluoromethoxyphenyl)sulfonyl]amino}cyclohexyl)-2-[(3S)-3-fluoropyrrolidin-1-yl]-2-oxoethanaminium chloride and (1S)-1-(trans-4-{[(2,4-difluorophenyl)sulfonyl]amino}cyclohexyl)-2-[(3S)-3-fluoropyrrolidin-1-yl]-2-oxoethanaminium chloride (MRL-A and MRL-B), containing a fluoropyrrolidine moiety in the structure, to undergo metabolic activation. The irreversible binding of these tritium-labeled compounds to rat liver microsomal protein was time- and NADPH-dependent and was attenuated by the addition of reduced glutathione (GSH) or N-acetylcysteine (NAC) to the incubation, indicating that chemically reactive intermediates were formed and trapped by these nucleophiles. Mass spectrometric analyses and further trapping experiments with semicarbazide indicated that the fluoropyrrolidine ring had undergone sequential oxidation and defluorination events resulting in the formation of GSH or NAC conjugates of the pyrrolidine moiety. The bioactivation of MRL-A was catalyzed primarily by rat recombinant CYP3A1 and CYP3A2. Pretreatment of rats with prototypic CYP3A1 and 3A2 inducers (pregnenolone-16α-carbonitrile and dexamethasone) enhanced the extent of bioactivation which, in turn, led to a higher degree of in vitro irreversible binding to microsomal proteins (5- and 9-fold increase, respectively). Herein, we describe studies that demonstrate that the fluoropyrrolidine ring is prone to metabolic activation and that GSH or NAC can trap the reactive intermediates to form adducts that provide insight into the mechanisms of bioactivation.This publication has 17 references indexed in Scilit:
- Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitorsBioorganic & Medicinal Chemistry Letters, 2004
- Drug−Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and DevelopmentChemical Research in Toxicology, 2003
- Insulin sensitisation in the treatment of Type 2 diabetesExpert Opinion on Investigational Drugs, 2003
- Sulfonylureas Differ in Effects on Ischemic Preconditioning—Is it Time to Retire Glyburide?Journal of Clinical Endocrinology & Metabolism, 2003
- Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2003
- New Concepts in Immunology Relevant to Idiosyncratic Drug Reactions: The “Danger Hypothesis” and Innate Immune SystemChemical Research in Toxicology, 1999
- Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IVEuropean Journal of Medicinal Chemistry, 1997
- In vitrometabolic transformations of 2,4- dipyrrolidinylp yrimidine : a chemical probe for P450-mediated oxidation of tirilazad mesylateXenobiotica, 1997
- Mass spectrometry in the analysis of glutathione conjugatesJournal of Mass Spectrometry, 1993
- Covalent and Noncovalent Interactions in Acute Lethal Cell Injury Caused by ChemicalsAnnual Review of Pharmacology and Toxicology, 1990